Journal of Clinical Chemistry and Laboratory Medicine
Open Access

Medullary Thyroid Carcinoma with Normal Calcitonin: Case Report with a Typical Presentation and Poor Prognosis

Jivago Da Fonseca Lopes^*, Laydner JP, Andrade LB, Fuhrmann DA, Romani F and Weinert LS ^*Correspondence: Jivago Da Fonseca Lopes, Federal University of Pelotas, Brazil, Tel: +55 53981582307, Email:

Author info »

Case Presentation

A 56-year-old man was referred for investigation of interscapular pain and lower limb paresis for 2 months, with a previous history of type 2 diabetes mellitus and smoking. Computed tomography of the chest and spine showed multiple osteolytic lesions in costal arches, diffuse vertebral bodies and the left iliac, in addition to infiltration and major obliteration of the vertebral canal. Biopsy of the thoracic spine injury was compatible with undifferentiated malignancy with characteristics of carcinoma with a possible primary thyroid site. Thyroid ultrasound was requested, which showed a heterogeneous nodule with defined margins, with cystic areas and hyperechogenic foci, measuring 1.7 × 1.1 × 1.1 cm. The fine needle puncture cytology revealed thyroid carcinoma and immune histochemistry compatible with medullary thyroid carcinoma (CMT). The serum CT level was less than 2 pg/ml and the CEA was 3.23 ng/ml, both within normal limits. The CT was evaluated in two collections with sample dilution in order to detect possible hook effect; all results showed normal CT. The genetic screening for mutations in exons 10, 11, 13, 14, 15 and 16 of the RET proto-oncogene was negative. After a discussion among endocrinologists, a team of head and neck surgeons and a patient, the decision was not to undergo thyroidectomy due to the extremely advanced disease, and we opted for clinical management with vandetanib. The patient underwent thoracic spine arthrodesis due to spinal compression and was discharged for outpatient follow-up, not returning to follow up.

Discussion

CMT is a neuroendocrine tumor originating from parafolicular thyroid C cells with an incidence ranging from 1 to 10% [1]. It can occur sporadically or in a hereditary form, which is associated with mutation of the germline of the RET protooncogene. It may present as a family form, as part of multiple endocrine neoplasia type 2A (MEN2A), combination of pheochromocytoma and hyperparathyroidism and type 2B (MEN2B), more common in childhood and associated with pheochromocytoma, mucosal neuromas, gastrointestinal neurogangliomatosis, megacolon and with worse prognosis. There is also the sporadic form whose tumor is well differentiated, with a slow growth rate and local aggressiveness [1,2]. CMT is associated with the production of calcitonin (CT) and carcinoembryonic antigen (CEA), which are generally related to mass size and prognosis, are part of the diagnosis and are useful in monitoring [3].

Due to the aggressiveness of this tumor, early identification, surgical resection and careful postoperative surveillance are extremely important. The serum TC level has important sensitivity and specificity when at baseline levels above 100 pg/ml. However, elevated levels may also be present in patients with autoimmune thyroid diseases, in heavy smokers, in advanced stages of kidney disease and in patients with pancreatic lung cancer [4]. It is possible to perform a differential diagnosis of a pentagastrin stimulating test, which shows an increase in TC above 1000 pg/ml, in addition to the serum CEA measurement [5]. Currently, new tests are proposed for diagnosis, such as the determination of calcitonin levels in fine needle aspiration fluid (FNAP), serum proCT measurement; peptide related to the calcitonin gene (CgA) and stimulated CT [6].

Few reports in the literature are associated with normal or negative levels of TC, being the first description of the 1980s [7,8]. A recent literature review on the topic found 49 described cases of CMT with atypical calcitonin values [9]. The pathophysiology of reduced or absent secretion in CMT differs from the literature, some of the hypotheses deal with a possible hook effect in the sample analyzed, another argues that there may be a differentiation process in parafolicular cells, compromising CT secretion [2]. The most widely accepted hypothesis currently supported by the American Thyroid Association suggests that the aggressiveness and differentiation of certain CMT subtypes causes a loss of the ability to produce CT [10]. Our case had a worse prognosis than the other previously reported cases, presenting itself on arrival at the hospital with distant metastases, which significantly impaired functionality. The patient did not return to the clinic for followup in 2 months due to possible death.

Treatment is similar to that of CMT with increased CT, total thyroidectomy and lymphadenectomy, in accordance with current guidelines [3]. In very advanced cases like the one described here, it is accepted not to perform the cervical surgical approach [11]. Chemotherapy and radiation therapy can be used in cases of advanced disease. The follow-up of these patients is a challenge, due to the absence of serum biomarkers such as CT. Thus, post-operative surveillance with imaging tests, including ultrasound and computed tomography of the neck, magnetic resonance imaging of the liver and chest, is necessary due to the difficult identification of distant metastases in these cases [12].

Conclusion

Non-calcitonin producing CMT is a rare and challenging entity, associated with a poor prognosis. It requires a high degree of suspicion on the part of physicians in order to avoid a late diagnosis in advanced stages of the disease and presenting, in the great majority, a reserved prognosis.

Acknowledgements

We authors thank our friends in the department of medical laboratory sciences for their unreserved assistance.

References

1. Trimboli P, Giovanella L. Serum calcitonin negative medullary thyroid carcinoma: A systematic review of the literature. Clin Chem Lab Med.2015;53:1507-1514.
2. Dora JM, da Silva Canalli MHB, Capp C, Puñales MK, Vieira JGH, Maia AL. Normal Perioperative Serum Calcitonin Levels in Patients with Advanced Medullary Thyroid Carcinoma: Case Report and Review of the Literature. Thyroid.2008;18:895-899.
3. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid.2009;19:565-612.
4. Alapat DV, Ain KB, Sloan DA, Monaghan KG, Karabakhtsian RG. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma. Endocrine.2011;39:148-152.
5. Hazard, John B, Hawk, William A, Crile G. The Department of Anatomic Pathology, and the Department of General Surgery, The Cleveland Clinic Foundation, and The Frank E. Bunts Educational Institute, Cleveland, Ohio. J Clin Endocrinol Metab.1958;19:152-161.
6. Trimboli P, Cremonini N, Ceriani L, Saggiorato E, Guidobaldi L, Romanelli F, et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: A retrospective multicentre study. Clin Endocrinol.2014;80:135-140.
7. Samà MT, Rossetto Giaccherino R, Gallo M, Felicetti F, Maletta F, Bonelli N, et al. Clinical challenges with calcitonin-negative medullary thyroid carcinoma. J Cancer Res Clin Oncol.2016;142:2023-2029.
8. Selby, Joe V, Friedman, Gary D, Quesenberry Charles P, Weiss NS. The New England Journal of Medicine Downloaded from www.nejm.org at UNIVERSITY OF MICHIGAN on December 9, 2010. For personal use only. No other uses without permission. Copyright © 1992 Massachusetts Medical Society. All rights reserved. N Engl J Med.1992;326:653-657.
9. Gambardella C, Offi C, Patrone R, Clarizia G, Mauriello C, Tartaglia E, et al. Calcitonin negative Medullary Thyroid Carcinoma: A challenging diagnosis or a medical dilemma? BMC Endocr Disord.2019;19:1-12.
10. Bockhorn M, Frilling A, Rewerk S, Liedke M, Dirsch O, Schmid KW, et al. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid.2004;14:468-470.
11. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid.2015;25:567-610.
12. Brutsaert EF, Gersten AJ, Tassler AB, Surks MI. Medullary thyroid cancer with undetectable serum calcitonin. J Clin Endocrinol Metab.2015;100:337-341.